English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In this study we aimed to test the activity of curcumin, a polyphenolic compound with known anticancer properties, in two breast cancer cell lines with different phenotypes: MCF-7 cell line as luminal B model and SK-BR-3 as HER2-amplified cancer cell model. As assayed by flow cytometric measurements 72 h curcumin treatment blocked the cell cycle progression of MCF-7 cells in G2/M phase, while for SK-BR-3 cells the cell cycle evolution was blocked less efficiently in the S phase. Curcumin reduced the clonogenic survival of both cell lines with EC50 values in the low micromolar range for the 48 h treatment period, SK-BR-3 being slightly more affected. In MCF-7 cells, curcumin reduced the expression level of ERK and its phosphorylation (Y204). Short term (0 to 120 min) treatment with curcumin increased the ROS production in both cell lines, but the effect was more pronounced in MCF-7 cells. In both cell lines, 48 h of 25 μM curcumin treatment induced mitochondrial membrane depolarization, with similar EC50 values. In conclusion, curcumin had anticancer effects in both cancer cell lines phenotypes, indicating its potential therapeutic usefulness against different types of breast cancer.

Anticancer effects of curcumin in luminal B and HER2 breast cancer cell line models